ITEM VIEW

Prostate cancer management - Helping your patient choose what is best for him

dc.contributor.authorHeyns C.F.
dc.contributor.authorVan der Merwe A.
dc.date.accessioned2011-05-15T16:17:57Z
dc.date.available2011-05-15T16:17:57Z
dc.date.issued2008
dc.identifier.citationSouth African Family Practice
dc.identifier.citation50
dc.identifier.citation5
dc.identifier.issn1726426X
dc.identifier.urihttp://hdl.handle.net/10019.1/14443
dc.description.abstractThe biggest problems in prostate cancer management are how to identify patients with potentially life-threatening cancer, and how to choose the best form of management from among the large array of treatment options. Although prostate cancer is the second or third most common cause of cancer death in males, most men with this diagnosis will die of other causes. The most important prognostic factors are the patient's life expectancy, the grade and stage of the tumour and the serum prostate specific antigen (PSA) at diagnosis. The most important management options are (1) active surveillance (watchful waiting), (2) androgen deprivation therapy (ADT), (3) radical prostatectomy and (4) radiotherapy. Patients with a limited life expectancy or non-aggressive cancer can be managed with active surveillance and be treated only if and when it becomes necessary. ADT (hormone therapy) provides excellent palliation in men with locally advanced or metastatic cancer, but the side-effects decrease quality of life. Radical prostatectomy and radiotherapy are potentially curative if the cancer is localised to the prostate. The use of laparoscopic radical prostatectomy is increasing in affluent countries, although (apart from reduced blood loss) there are no significant advantages compared to retropubic or perineal radical prostatectomy. The main complications are erectile dysfunction and urinary incontinence. The use of brachytherapy is increasing, although there is no convincing evidence that it is more effective or has fewer complications than external beam radiotherapy. Although a vast amount of information on prostate cancer is available on the internet, some of the websites are driven by financial incentives to promote their products or procedures, and patients may emerge with unrealistic expectations based on misinformation. There are certain websites, based on the Partin tables or the Kattan nomogram, which can be used by the doctor to calculate the patient's statistical probability of being cured with radical prostatectomy of radiotherapy. The probability of cure has to be weighed up against the risk of complications or side-effects that impair quality of life. There are very few randomised clinical trials comparing treatment options, so there is no real answer to the question which form of management is "best". Patients and their families should be given comprehensive and unbiased information and sufficient time to make decisions. Because there are no absolutely right or wrong choices, and because patients all have different expectations, it is best for the patient himself to decide what form of management would be best for him.
dc.subjectantiandrogen
dc.subjectbicalutamide
dc.subjectbuserelin
dc.subjectcyproterone acetate
dc.subjectdes
dc.subjectdiethylstilbestrol
dc.subjectdocetaxel
dc.subjectestradiol
dc.subjectestrofem
dc.subjectestrogen
dc.subjectflutamide
dc.subjectgonadorelin agonist
dc.subjectgoserelin
dc.subjecthydrocortisone
dc.subjectketoconazole
dc.subjectleuprorelin
dc.subjectmitoxantrone
dc.subjectprostate specific antigen
dc.subjecttriptorelin
dc.subjectunclassified drug
dc.subjectadvanced cancer
dc.subjectanemia
dc.subjectanxiety
dc.subjectarticle
dc.subjectbody fat
dc.subjectbrachytherapy
dc.subjectcancer chemotherapy
dc.subjectcancer grading
dc.subjectcancer hormone therapy
dc.subjectcancer localization
dc.subjectcancer palliative therapy
dc.subjectcancer radiotherapy
dc.subjectcancer staging
dc.subjectcerebrovascular accident
dc.subjectclinical protocol
dc.subjectclinical trial
dc.subjectcognitive defect
dc.subjectcryotherapy
dc.subjectdeep vein thrombosis
dc.subjectdepression
dc.subjectdrug efficacy
dc.subjecterectile dysfunction
dc.subjectexternal beam radiotherapy
dc.subjectgynecomastia
dc.subjectheart failure
dc.subjectheart infarction
dc.subjecthigh intensity focused ultrasound
dc.subjecthot flush
dc.subjecthuman
dc.subjecthypertension
dc.subjecthyperthermic therapy
dc.subjectlaparoscopic surgery
dc.subjectlibido disorder
dc.subjectlife expectancy
dc.subjectlung embolism
dc.subjectmale
dc.subjectmastalgia
dc.subjectmetastasis
dc.subjectmuscle mass
dc.subjectorchiectomy
dc.subjectosteoporosis
dc.subjectphotodynamic therapy
dc.subjectprognosis
dc.subjectprostate cancer
dc.subjectprostatectomy
dc.subjectquality of life
dc.subjectside effect
dc.subjectsodium retention
dc.subjecturine incontinence
dc.subjectwater retention
dc.titleProstate cancer management - Helping your patient choose what is best for him
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW